Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2010

Open Access 01-12-2010 | Primary research

Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria

Authors: Jayesh Sagar, Kevin Sales, Jan-Willem Taanman, Sas Dijk, Marc Winslet

Published in: Cancer Cell International | Issue 1/2010

Login to get access

Abstract

Background

Colorectal cancer is the third most-common cancer and the second most-common cause of cancer related death in UK. Although chemotherapy plays significant role in the treatment of colorectal cancer, morbidity and mortality due to drug resistance and cancer metastasis are yet to be eliminated. Recently, doxycycline has been reported to have cytotoxic and anti-proliferating properties in various cancer cells. In this study, whether doxycycline was apoptosis threshold lowering agent in colorectal cancer cells by targeting mitochondria was answered.

Results

This study showed dose-dependent cytotoxic effects of cisplatin, oxaliplatin and doxycycline in HT29 colorectal cancer cells. Doxycycline showed inhibition of cytochrome-c- oxidase activity in these cells over a time-period. The pre-treatment of doxycycline reported statistically significant increased cytotoxicity of cisplatin and oxaliplatin compared to cisplatin and oxaliplatin alone. The caspase studies revealed significantly less expression and activity of caspase 3 in HT29 cells pre-treated with doxycycline compared to the cells treated with cisplatin and oxaliplatin alone.

Conclusions

It was concluded that doxycycline lowered the apoptotic threshold in HT 29 cells by targeting mitochondria. This also raised possible caspase-independent mechanisms of apoptosis in HT29 cells when pre-treated with doxycycline however this needs further research work.
Appendix
Available only for authorised users
Literature
1.
Saikali Z, Singh G: Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs. 2003, 14: 773-778. 10.1097/00001813-200311000-00001.CrossRefPubMed
2.
Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 2002, 98: 297-309. 10.1002/ijc.10168.CrossRefPubMed
3.
Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson WG: Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis. 1998, 16: 217-225. 10.1023/A:1006588708131.CrossRefPubMed
4.
Cakir Y, Hahn KA: Direct action by doxycycline against canine osteosarcoma cell proliferation and collagenase (MMP-1) activity in vitro. In Vivo. 1999, 13: 327-331.PubMed
5.
Duivenvoorden WC, Popovic SV, Lhotak S, Seidlitz E, Hirte HW, Tozer RG: Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Cancer Res. 2002, 62: 1588-1591.PubMed
6.
Iwasaki H, Inoue H, Mitsuke Y, Badran A, Ikegaya S, Ueda T: Doxycycline induces apoptosis by way of caspase-3 activation with inhibition of matrix metalloproteinase in human T-lymphoblastic leukemia CCRF-CEM cells. J Lab Clin Med. 2002, 140: 382-386. 10.1067/mlc.2002.129308.CrossRefPubMed
7.
Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR: Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem. 2001, 8: 261-270.CrossRefPubMed
8.
D'Agostino P, Ferlazzo V, Milano S, La RM, Di BG, Caruso R: Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway. Int Immunopharmacol. 2003, 3: 63-73. 10.1016/S1567-5769(02)00213-8.CrossRefPubMed
9.
Schwartz LM, Smith SW, Jones ME, Osborne BA: Do all programmed cell deaths occur via apoptosis?. Proc Natl Acad Sci USA. 1993, 90: 980-984. 10.1073/pnas.90.3.980.PubMedCentralCrossRefPubMed
10.
Thornberry NA, Lazebnik Y: Caspases: enemies within. Science. 1998, 281: 1312-1316. 10.1126/science.281.5381.1312.CrossRefPubMed
11.
Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T: Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol. 2002, 50: 343-352. 10.1007/s00280-002-0522-7.CrossRefPubMed
12.
Makin G, Dive C: Recent advances in understanding apoptosis: new therapeutic opportunities in cancer chemotherapy. Trends Mol Med. 2003, 9: 251-255. 10.1016/S1471-4914(03)00084-4.CrossRefPubMed
13.
Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin. 1999, 49: 33-64. 10.3322/canjclin.49.1.33. 1CrossRefPubMed
14.
Onoda T, Ono T, Dhar DK, Yamanoi A, Fujii T, Nagasue N: Doxycycline inhibits cell proliferation and invasive potential: combination therapy with cyclooxygenase-2 inhibitor in human colorectal cancer cells. J Lab Clin Med. 2004, 143: 207-216. 10.1016/j.lab.2003.12.012.CrossRefPubMed
15.
Onoda T, Ono T, Dhar DK, Yamanoi A, Nagasue N: Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 2006, 118: 1309-1315. 10.1002/ijc.21447.CrossRefPubMed
16.
Fife RS, Sledge GW, Roth BJ, Proctor C: Effects of doxycycline on human prostate cancer cells in vitro. Cancer Lett. 1998, 127: 37-41. 10.1016/S0304-3835(98)00003-2.CrossRefPubMed
17.
Fife RS, Rougraff BT, Proctor C, Sledge GW: Inhibition of proliferation and induction of apoptosis by doxycycline in cultured human osteosarcoma cells. J Lab Clin Med. 1997, 130: 530-534. 10.1016/S0022-2143(97)90130-X.CrossRefPubMed
18.
Mouratidis PX, Colston KW, Dalgleish AG: Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells. Int J Cancer. 2007, 120: 743-752. 10.1002/ijc.22303.CrossRefPubMed
Metadata
Title
Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria
Authors
Jayesh Sagar
Kevin Sales
Jan-Willem Taanman
Sas Dijk
Marc Winslet
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2010
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-10-31

Other articles of this Issue 1/2010

Cancer Cell International 1/2010 Go to the issue

Primary research

A cancer derived mutation in the Retinoblastoma gene with a distinct defect for LXCXE dependent interactions

Primary research

Determination of the differentiation capacities of murines' primary mononucleated cells and MC3T3-E1 cells

Primary research

Transformation of SV40-immortalized human uroepithelial cells by 3-methylcholanthrene increases IFN- and Large T Antigen-induced transcripts

Primary research

ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

Primary research

Comparison of lung cancer cell lines representing four histopathological subtypes with gene expression profiling using quantitative real-time PCR

Review

Wnt signal transduction pathway and apoptosis: a review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits